Editas Medicine Inc

NASDAQ:EDIT

41.50

+1.14 (+2.82%)

4:15:14 PM EDT: $41.79 +0.29 (+0.70%)

Market Cap (Intraday)	2.88B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$6.38 Million
Adjusted EPS	-$0.76

See more estimates

10-Day MA	$45.22
50-Day MA	$63.85
200-Day MA	$41.23

See more pivots

Editas Medicine, Inc. Stock, NASDAQ:EDIT

11 Hurley Street, 11 Hurley Street, Cambridge, Massachusetts 02142

United States of America

Phone: +1.617.401.9000

Number of Employees: 208

http://www.editasmedicine.com

Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.